Predictors of contrast-induced nephropathy in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention

Association between elevated CHA2DS2-VASC score and contrast-induced nephropathy among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

BACKGROUND

Promising results with the CHA2DS2-VASc risk score (CVRS) have been reported for the prediction of contrast-induced nephropathy (CIN). The aim of this study is to consolidate all the data available and examine the association between elevated CVRS and the incidence of CIN in patients undergoing percutaneous coronary intervention (PCI).

METHODS

We systematically searched PubMed, Embase, and Scopus for abstracts and full-text articles from inception to May 2022. Studies were included if they evaluated the association between a high CVRS and the incidence of CIN in patients undergoing PCI. Data were integrated using the random-effects, generic inverse variance method of DerSimonian and Laird. Prospero registration: CRD42022334065.

RESULTS

Seven studies from 2016 to 2021 with a total of 7,401 patients were included. In patients undergoing PCI, a high CVRS (≥2: Odds ratio [OR]:2.98, 95% confidence interval [95% CI] 2.25-3.94, p < .01, I2 = 1%, ≥3: OR 4.46, 95% CI 2.27-8.78, p < .01, I2=56% and ≥4: OR:2.75, 95% CI 1.76-4.30, p < .01, I2 = 11%) was significantly associated with an increase incidence for CIN. Subgroup analyses were done in patients with acute coronary syndrome, and association with CIN remained statistically significant (≥2: OR 2.93, 95% CI 2.11-4.07, p < .01, I2=22%and ≥4: OR:2.24, 95% CI 1.36-3.69, p < .01, I2 = 0%,).

CONCLUSION

In patients undergoing PCI, an elevated CVRS is associated with an increased risk for CIN. More rigorous studies are needed to clarify this association and to identify strategies to reduce CIN.

The utility of systemic immune-inflammation index for predicting contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

OBJECTIVE

The systemic immune-inflammation index (SII), derived from counts of neutrophil, platelet and lymphocyte, have been developed to predict clinical outcomes in several cancers and cardiovascular diseases. The aim of this study was to evaluate the utility of SII to predict contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).

METHODS

A total of 632 patients with STEMI who underwent primary PCI were retrospectively included. The patients divided into two groups based on the presence or absence of CIN. Baseline demographic, laboratory and clinic characteristics were evaluated between the two groups. Logistic regression analysis was used to identify independent predictors of CIN.

RESULTS

The receiver-operating characteristic (ROC) curve analysis demonstrated that the optimal cut-off value of SII for predicting CIN was 1282 with a sensitivity 76.1% and specificity 86.7% (AUC: 0.834; 95% CI 0.803-0.863; p<0.001). Multivariate analysis performed in two models (SII; as separate continuous and categorical variables) showed age, estimated glomerular filtration rate (eGFR), diabetes, left ventricular ejection fraction (LVEF), Killip class ≥2, use of intravenous diuretic, Troponin I, and SII as independent predictors of CIN in Model 1. In Model 2, age, eGFR, diabetes, LVEF, Killip class ≥2, use of intravenous diuretic, Troponin I, and a value of SII >1282 (p<0.001, OR 6.205, 95% CI 2.301-12.552) remained as independent predictors of CIN.

CONCLUSION

SII may be a useful and reliable indicator to predict the development of CIN in patients with STEMI undergoing primary PCI than NLR and PLR.